Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework

Emily Bain, Tanya Bubner, Philippa Middleton, Pat Ashwood, Emer Van Ryswyk, Lucy Simmons, Sally Reid, Caroline A Crowther

Research output: Contribution to journalMeeting Abstract

Abstract

Strong evidence supports the use of antenatal magnesium sulphate before birth at less than 30 weeks’ gestation to reduce the risk of death and cerebral palsy for very preterm babies. This study was undertaken to assess health professionals’ self reported use of this neuroprotective therapy, and barriers and enablers to implementation of Australian and New Zealand clinical practice guidelines.
Original languageEnglish
Pages (from-to)30
Number of pages1
JournalJournal of Paediatrics and Child Health
Volume51
Issue numberSuppl 1
DOIs
Publication statusPublished - Apr 2015
EventPerinatal Society of Australia and New Zealand 19th Annual Congress - Crown Promenade, Melbourne, Australia
Duration: 19 Apr 201522 Apr 2015
Conference number: 19

Keywords

  • fetal neuroprotection
  • Antenatal care
  • magnesium sulphate
  • neuroprotective therapy

Fingerprint Dive into the research topics of 'Barriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: A study using the theoretical domains framework'. Together they form a unique fingerprint.

  • Cite this